ALPEK. de Past Earnings Performance
Past criteria checks 0/6
ALPEK. de's earnings have been declining at an average annual rate of -36.8%, while the Chemicals industry saw earnings growing at 10.7% annually. Revenues have been growing at an average rate of 6.4% per year.
Key information
-36.8%
Earnings growth rate
-36.7%
EPS growth rate
| Chemicals Industry Growth | 13.1% |
| Revenue growth rate | 6.4% |
| Return on equity | -26.8% |
| Net Margin | -7.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Why We're Not Concerned About ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Share Price
Oct 11
Returns On Capital Signal Difficult Times Ahead For ALPEK. de (BMV:ALPEKA)
Sep 12Should You Investigate ALPEK, S.A.B. de C.V. (BMV:ALPEKA) At Mex$11.86?
Aug 21ALPEK, S.A.B. de C.V. Just Missed Earnings - But Analysts Have Updated Their Models
Jul 27A Look At The Intrinsic Value Of ALPEK, S.A.B. de C.V. (BMV:ALPEKA)
Jun 21Some Investors May Be Worried About ALPEK. de's (BMV:ALPEKA) Returns On Capital
Jun 06Earnings Miss: ALPEK, S.A.B. de C.V. Missed EPS By 51% And Analysts Are Revising Their Forecasts
Apr 25What ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) P/S Is Not Telling You
Apr 13At Mex$12.61, Is ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Worth Looking At Closely?
Mar 26ALPEK. de (BMV:ALPEKA) Has A Somewhat Strained Balance Sheet
Mar 08A Look At The Intrinsic Value Of ALPEK, S.A.B. de C.V. (BMV:ALPEKA)
Jan 22Investor Optimism Abounds ALPEK, S.A.B. de C.V. (BMV:ALPEKA) But Growth Is Lacking
Jan 04Is There Now An Opportunity In ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?
Dec 14ALPEK. de (BMV:ALPEKA) Use Of Debt Could Be Considered Risky
Nov 24Is Now The Time To Look At Buying ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?
Sep 02ALPEK. de (BMV:ALPEKA) Has A Somewhat Strained Balance Sheet
Jul 16ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Intrinsic Value Is Potentially 91% Above Its Share Price
Jun 27The ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Analysts Have Been Trimming Their Sales Forecasts
Apr 30When Should You Buy ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?
Apr 20An Intrinsic Calculation For ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Suggests It's 34% Undervalued
Mar 28These Analysts Think ALPEK, S.A.B. de C.V.'s (BMV:ALPEKA) Sales Are Under Threat
Feb 25Is ALPEK. de (BMV:ALPEKA) A Risky Investment?
Feb 23Is It Too Late To Consider Buying ALPEK, S.A.B. de C.V. (BMV:ALPEKA)?
Jan 07Estimating The Intrinsic Value Of ALPEK, S.A.B. de C.V. (BMV:ALPEKA)
Dec 22At Mex$26.92, Is ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Worth Looking At Closely?
Sep 24We Think ALPEK. de (BMV:ALPEKA) Can Stay On Top Of Its Debt
Aug 30Should You Think About Buying ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Now?
Jun 18Analysts Just Made A Neat Upgrade To Their ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Forecasts
May 28These 4 Measures Indicate That ALPEK. de (BMV:ALPEKA) Is Using Debt Reasonably Well
May 05Growth Investors: Industry Analysts Just Upgraded Their ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Revenue Forecasts By 11%
Feb 21Is ALPEK. de (BMV:ALPEKA) A Risky Investment?
Feb 01An Intrinsic Calculation For ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Suggests It's 23% Undervalued
Jan 10Is ALPEK, S.A.B. de C.V. (BMV:ALPEKA) Potentially Undervalued?
Dec 24ALPEK. de (BMV:ALPEKA) Seems To Use Debt Quite Sensibly
Oct 26Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How ALPEK. de makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 132,434 | -10,103 | 5,622 | 0 |
| 30 Jun 24 | 128,647 | -11,026 | 5,492 | 0 |
| 31 Mar 24 | 131,934 | -10,686 | 5,668 | 0 |
| 31 Dec 23 | 138,159 | -10,914 | 5,896 | 0 |
| 30 Sep 23 | 156,683 | 767 | 6,144 | 0 |
| 30 Jun 23 | 183,065 | 3,453 | 6,522 | 0 |
| 31 Mar 23 | 203,133 | 8,955 | 6,846 | 0 |
| 31 Dec 22 | 212,435 | 13,744 | 6,959 | 0 |
| 30 Sep 22 | 208,689 | 13,602 | 7,364 | 0 |
| 30 Jun 22 | 190,591 | 13,576 | 7,042 | 0 |
| 31 Mar 22 | 171,271 | 10,001 | 6,499 | 0 |
| 31 Dec 21 | 156,224 | 7,756 | 6,095 | 0 |
| 30 Sep 21 | 140,268 | 9,175 | 5,673 | 0 |
| 30 Jun 21 | 127,927 | 8,392 | 5,429 | 0 |
| 31 Mar 21 | 118,297 | 6,028 | 5,438 | 0 |
| 31 Dec 20 | 113,989 | 3,123 | 5,440 | 0 |
| 30 Sep 20 | 112,413 | 5,151 | 5,313 | 0 |
| 30 Jun 20 | 112,662 | 4,691 | 5,176 | 0 |
| 31 Mar 20 | 116,640 | 5,635 | 5,083 | 0 |
| 31 Dec 19 | 119,685 | 6,605 | 4,961 | 0 |
| 30 Sep 19 | 127,354 | 10,373 | 5,110 | 0 |
| 30 Jun 19 | 134,627 | 10,913 | 5,221 | 0 |
| 31 Mar 19 | 137,345 | 12,601 | 5,384 | 0 |
| 31 Dec 18 | 134,523 | 13,633 | 5,323 | 0 |
| 30 Sep 18 | 124,731 | 5,240 | 6,892 | 0 |
| 30 Jun 18 | 111,272 | -3,406 | 6,467 | 0 |
| 31 Mar 18 | 101,404 | -5,707 | 6,022 | 0 |
| 31 Dec 17 | 98,998 | -5,487 | 5,884 | 0 |
| 30 Sep 17 | 97,416 | -4,366 | 3,807 | 0 |
| 30 Jun 17 | 97,173 | 3,697 | 3,831 | 0 |
| 31 Mar 17 | 95,240 | 4,112 | 3,775 | 0 |
| 31 Dec 16 | 90,192 | 3,625 | 3,665 | 0 |
| 30 Sep 16 | 87,174 | 3,558 | 3,630 | 0 |
| 30 Jun 16 | 86,103 | 3,248 | 3,526 | 0 |
| 31 Mar 16 | 85,161 | 3,654 | 3,434 | 0 |
| 31 Dec 15 | 83,590 | 2,748 | 3,247 | 0 |
| 30 Sep 15 | 85,981 | 1,844 | 3,046 | 0 |
| 30 Jun 15 | 85,331 | 1,615 | 2,866 | 0 |
| 31 Mar 15 | 84,935 | 860 | 2,678 | 0 |
| 31 Dec 14 | 86,072 | 801 | 2,565 | 0 |
| 30 Sep 14 | 84,225 | 1,105 | 2,411 | 0 |
| 30 Jun 14 | 86,022 | 1,248 | 2,351 | 0 |
| 31 Mar 14 | 87,636 | -198 | 2,292 | 0 |
| 31 Dec 13 | 90,061 | 262 | 2,210 | 0 |
Quality Earnings: ALPEK A is currently unprofitable.
Growing Profit Margin: ALPEK A is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALPEK A is unprofitable, and losses have increased over the past 5 years at a rate of 36.8% per year.
Accelerating Growth: Unable to compare ALPEK A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALPEK A is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-6.6%).
Return on Equity
High ROE: ALPEK A has a negative Return on Equity (-26.79%), as it is currently unprofitable.